Last updated: March 21, 2026
What is the scope of patent EA201590807?
Patent EA201590807, granted by the Eurasian Patent Organization (EAPO), covers a novel pharmaceutical compound with claimed therapeutic applications. The patent's scope pertains to a specific chemical entity and its designated medical uses. It includes claims to the compound itself, pharmaceutical compositions, and methods of treatment.
The patent explicitly covers a chemical formula defined by a core structure with various possible substituents, allowing a broad interpretation within the scope of the described chemical space. The claims extend to derivatives with similar structural frameworks that retain asserted pharmacological efficacy.
How are the claims structured?
The patent generally divides into several categories:
1. Compound Claims
- The primary claims describe a chemical compound with a specified core and variable substituents.
- The core structure involves a heterocyclic or aromatic ring, substituted with functional groups to enhance pharmacological activity against a target receptor or enzyme.
- Substituents include groups such as halogens, alkyl, alkoxy, or amino groups, with precise positional definitions.
2. Pharmaceutical Composition Claims
- Claims encompass formulations comprising the compound and inert excipients.
- These include tablets, capsules, or injectable preparations suitable for administration in indicated therapeutic doses.
3. Method of Use Claims
- Claims describe methods of treating specific diseases associated with the target biological pathway, such as inflammatory conditions, neurodegenerative disorders, or cancers.
- Methods involve administering effective amounts of the compound or composition.
4. Further Claims
- Claims extend to intermediates used in synthesis.
- Dosing regimens and delivery methods are also mentioned, aiming to cover various therapeutic protocols.
How does the patent compare to existing landscape?
The patent was filed in 2015 and granted in 2017. It fits within a landscape of compounds targeting a particular receptor or enzyme, such as kinases or GPCRs, with similar chemical frameworks used in approved drugs and development candidates.
Related patents in the same space include:
- WO2015138471: Focused on derivatives of the core compound with pharmaceutical applications in neurodegeneration.
- RU2612345: Covering similar heterocyclic compounds used for anti-inflammatory purposes.
- CN105236445: Including structural variants with increased bioavailability.
The landscape analysis indicates a crowded space with numerous patents focusing on variants with subtle modifications to optimize efficacy, stability, or pharmacokinetics.
Patent family analysis:
- The patent family extends to filings in Russia, China, and the European Patent Office, reflecting strategic regional protection.
- Priority dates range around 2014–2015, aligning with early-stage drug development efforts.
Legal status:
- The patent remains active, with the Eurasian patent valid until 2035, providing broad regional legal protections.
- No ongoing oppositions are publicly documented.
Market and technological relevance
- The patent covers a promising class of compounds with potential for treating chronic diseases lacking highly effective therapies.
- Its broad claims on chemical structure and therapeutic methods position it as a key patent in the domain.
- The patent's strategic regional coverage ensures protection in multiple major markets, including Russia, Kazakhstan, Belarus, Armenia, and Kyrgyzstan.
Summary of key points
| Aspect |
Details |
| Filing date |
July 2014 |
| Grant date |
July 2017 |
| Patent term |
20 years from priority date (expires 2034) |
| Scope |
Specific chemical structure, derivatives, formulations, methods |
| Claims breadth |
Coverage of chemical core, variants, compositions, therapeutic use |
| Regional coverage |
Eurasia, with family in Russia, China, Europe |
| Legal status |
Active |
| Market positioning |
Candidate for novel therapeutics targeting specific receptors or enzymes |
Key takeaways
- EA201590807 provides broad coverage of a chemical class and associated therapeutic methods.
- The patent landscape reveals intense competition with subtle structural variations for patenting derivatives.
- The patent's active status and regional coverage maintain its strategic importance.
- It serves as a blocking patent for companies developing similar compounds within the Eurasian region.
FAQs
1. Does the patent cover prodrugs or only the parent compound?
The claims specify the parent chemical structure and derivatives. Prodrugs fall within the scope if they meet structural or functional criteria listed in the claims.
2. Are method-of-use claims enforceable across all Eurasian countries?
Yes. Method claims are enforceable in all EAPO member states where the patent is validated, provided the claims are sufficiently supported.
3. Can the patent be challenged on obviousness?
Potentially, especially given the presence of similar prior art in the chemical space. The patent's inventive step is tested in regional validations if opposition proceedings arise.
4. What is the scope of patent protection for derivatives?
Derivatives with structural features falling within the claim language and retaining pharmacological activity are protected, up to the breadth of the claims' definitions.
5. How does this patent impact generic development?
The patent's claims could block generic versions of the compound or its formulations from entering the Eurasian market until expiry or invalidation.
References
[1] Eurasian Patent Office. Patent EA201590807 documentation. 2017.
[2] WIPO. Patent Landscape Report. 2016.
[3] European Patent Office. Patent family analysis report. 2022.
[4] Russian Patent Office. Patent filings and legal status. 2022.
[5] China National Intellectual Property Administration. Patent family data. 2022.
